Pink Sheet reporter and editors discuss key US and EU legislation that impacted 2023 and how it also could affect 2024, including EU legislative reform (:56), US Medicare drug price negotiations (14:43), and the US Food and Drug Administration user fee reauthorization (30:57). More On These Topics From The Pink Sheet European Commission Explains Impact Of EU Pharma Review On SMEs & Non-Profit Entities: https://pink.citeline.com/PS149505/European-Commission-Explains-Impact-Of-EU-Pharma-Review-On-SMEs--NonProfit-Entities Biopharma’s Prospects Under A Second Trump Term: They Can’t Get Much Worse: https://pink.citeline.com/PS149562/Biopharmas-Prospects-Under-A-Second-Trump-Term-They-Cant-Get-Much-Worse The following special topic pages include links to all of our coverage: EU Legislative Reform: https://pink.citeline.com/eu-legislative-reform FDA User Fees: https://pink.citeline.com/us-fda-user-fees Drug Pricing Debate: https://pink.citeline.com/pricing-debate

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related